undamentalytics Newsletter
Sign in

Arcturus Therapeutics Holdings Inc. income statement

In fiscal 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $82.0m, down 46.1% on the year before, operating income of −$76.3m (a -93.0% margin) and net income of −$65.8m, or −$2.40 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue162110122061671528229
Research and development17345817414819219511287
General and administrative211323414653534645
Operating income−22−26−72−20312−78−96−76−102
Income before tax−22−26−72−20411−28−81−66—
Income tax————12−0——
Net income−22−26−72−2049−30−81−66−93
Diluted EPS−$2.16−$2.15−$3.55−$7.74$0.35−$1.12−$3.00−$2.40−$3.33
Diluted shares (average)10m12m20m26m27m27m27m27m28m
EBITDA−21−25−71−20214−75−92−73−100

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARCT vs TNXPARCT vs GLUEARCT vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcturus Therapeutics Holdings Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcturus Therapeutics Holdings Inc.